Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | POLA1 | P09884 | 2/20 | 0.49 |
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606890 | 0.89 | POLB (0.49) | SLC22A6FGFR1POLBPOLA1POLG | |
| Pmedap SCHEMBL215611 | 0.88 | FGFR1 (0.72) | SLC22A6FGFR1POLBPOLA1POLG | |
| Pmedap SCHEMBL29571667 | 0.88 | FGFR1 (0.72) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL1566036 | 0.87 | FGFR1 (0.63) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL7601171 | 0.87 | FGFR1 (0.57) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL30759944 | 0.87 | FGFR1 (0.63) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL1567494 | 0.86 | FGFR1 (0.60) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL30824623 | 0.86 | FGFR1 (0.60) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL23015054 | 0.86 | SLC22A6 (0.62) | SLC22A6FGFR1POLBPOLA1POLG | |
| SCHEMBL29626981 | 0.86 | SLC22A6 (0.62) | SLC22A6FGFR1POLBPOLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8163718-B2 | Nucleoside analogues containing phosphonate or phosphonamide groups | GILEAD SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | TP53, ZC3HAV1, ZFX | SLC22A6 4711/4885FGFR1 628/4885POLB 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.